|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030
Abiant, Inc. Co-Authors Paper Published in Psychopharmacology
DEERFIELD, ILLINOIS, November 13, 2009. Abiant, Inc. announced today that a paper describing the
use of its neuroimaging methods to measure the effects of a novel compound has been published in
the journal Psychopharmacology. Dr. Mark Schmidt of the pharmaceutical company Johnson &
Johnson is lead author.
The paper describes the use of the radiotracer 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) and PET
imaging to measure the effects of a compound targeting the corticotropin releasing factor 1 (CRF1)
receptor system of the brain. The study, which used FDG PET and Abiant's data collection and analysis
methods, was designed to confirm whether the drug affected the brain, where the effect was, and how
this effect changed with two different doses of the drug. Even though a tracer specific to the CRF1
receptor is not available, the tracer FDG, which measures changes in glucose metabolism in the brain,
was able to provide important insight to the drug's effects using a group of 12 subjects when Abiant's
methods were applied.
Since the cost of bringing a drug forward to large trials is highly expensive, the use of imaging with
small groups of subjects early in development can provide important, cost- and risk- saving insight for
decision-making. These decisions may include dose setting for larger trials, and whether or not to
bring the compound forward in development.
Abiant found that the drug had an increasing response as dose increased, in regions including those
where the CRF1 receptor is known to be distributed. The abstract for the paper, which can be retrieved
on-line through the Psychopharmacology journal website, is included below.
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in
healthy male subjects.
Schmidt ME, Andrews RD, van der Ark P, Brown T, Mannaert E, Steckler T, de Hoon J, Van Laere K.
BACKGROUND: Corticotropin-releasing factor receptor type 1 (CRF(1)) antagonists have been
proposed as therapeutic agents in the treatment of mood and anxiety disorders although clinical
evidence supporting their development and understanding of a dose-response relationship has been
lacking. METHODS: We tested two doses of the CRF(1) antagonist R317573 for effects on regional
cerebral glucose metabolism (rCMglu) using [(18)F] fluoro-2-deoxy-D: -glucose (FDG) positron
emission tomography (PET) following single-dose challenges in a double-blind, placebo-controlled,
cross-over design, in 12 healthy male volunteers. RESULTS: Single 30- and 200-mg doses of
R317573 resulted in dose-related changes in rCMglu. Relative increases in rCMglu were observed in
frontal cortical regions while relative decreases occurred in the putamen and right amygdala after both
doses. Relative decreases occurred in cerebellum and right parahippocampal gyrus following the
higher dose. CONCLUSIONS: R317573 appears to produce acute dose-dependent changes in
rCMglu. Effects occurred in regions that may be behaviorally relevant to mood and anxiety disorders. In
some regions, these effects may be related to the receptor (target) density. Measuring acute effects on
rCMglu with FDG-PET may offer a method for defining pharmacologically active doses for central
nervous system targets for which selective radiotracers are lacking.
Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker of
drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, can be used to accelerate or reduce risk of decision making
in both drug development and disease treatment. The Company’s focus areas include PET imaging,
the central nervous system, and neurodegenerative disorders such as Alzheimer's Disease.
Forward Looking Statements
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.